Fusion Medical to develop FloSeal sealant from $9 million share offering
This article was originally published in Clinica
Fusion Medical Technologies plans to raise $9.3 million which will be used largely to commercialise FloSeal, a collagen-derived matrix with thrombin that controls surgical bleeding. In a secondary offering, the company intends to sell 1.7 million shares at an assumed offering price of around $6.17.
You may also be interested in...
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.
VMS businesses are deemed essential in Department of Homeland Security guidance that provides as basis for orders by most states and localities across the US. During an AHPA webinar, attorney Trent Norris says the federal government prefers leaving business exemptions to shut-down decisions to the states.
Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.